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Abstract
Background/Aim. During the first 10 years over 50% of
diabetes patients develop erectile dysfunction (ED). It is
more severe and resistant to therapy than in male patients
with normal glucoregulation. The purpose of this pilot study
was to estimate the tadalafil (Cialis) efficacy and safety in
male patients with diabetes mellitus (DM), together with
moderate to severe ED. Methods. The study included 30
male patients with diagnozed type 1 or type 2 DM together
with ED. ED was estimated through the International In-
dex of Erectile Function (IIEF-6), Sexual Encounter Profile
(SEP) questionnaire and prostaglandin test, at the beginning
of the research and three months after the 20 mg tadalafil
therapy initiation, once a week (on Fridays). Glycosylated
haemoglobin in blood (HbA1c) values were also monitored.
According to the ED severity (IIEF values at the beginning
of the therapy) the patients were divided into 2 groups. The
previous experience with sildenafil citrate (Viagra) and
prostaglandin E1 intracavernous therapy was recorded. Re-
sults. Tadalafil significantly improved ED (p < 0.001) for
7.40 points of the IIEF score, i.e. for 58% and 60% towards
SEP2 and SEP3 questionnaire, respectively. Compared to
the previous ED therapy subjectively better tadalafil experi-
ence was recorded. Each group experienced a significant
improvement in IIEF score (p < 0.001), more significantly
in the group 2 (8.26±1.49 points) compared with the me-
dium improvement in the group 1 (6.27±1.35 points). After
three months HbA1c values decreased for 2.26±1.62
(p < 0.001). Conclusion. Tadalafil is an effective tool for
treating ED in diabetes patients. In some situations tadalafil
application could replace prostaglandin test. The sexual
sphere motivation leads to the improvement of glucoregu-
lation in DM patients.
Key words:
diabetes mellitus; impotence; phosphodiesterase
inhibitors; drug therapy.
Apstrakt
Uvod/Cilj. Više od 50% obolelih od dijabetes melitusa
(DM) razvije erektilnu disfunkciju (ED) tokom prvih 10
godina od početka bolesti. Ona je mnogo teža i rezistent-
nija na terapiju nego kod muškaraca sa normalnom gliko-
regulacijom. Cilj rada bio je da se proceni efikasnost i
bezbednost tadalafila (Cialis) kod muškaraca sa DM i pri-
druženom umerenom do teškom ED. Metode. Studijom
je obuvaćeno 30 muškaraca sa dijagnozom DM tip I ili tip
II i pridruženom ED. Procena ED vršena je pomoću In-
ternacionalnog indeksa erektilne funkcije (IIEF-6), Sexual
Encounter Profile (SEP) upitnika i prostaglandinskog testa,
na početku istraživanja i nakon tri meseca od početka te-
rapije tadalafilom 20 mg, jedan put nedeljno (petak). Pra-
ćene su i vrednosti glikoliziranog hemoglobina u krvi
(HbA1c). Prema težini ED (vrednostima IIEF skora na
početku studije) bolesnici su bili podeljeni u dve grupe.
Beleženo je prethodno iskustvo sa sildenafil citratom (Vi-
agra) i intrakavernoznom terapijom prostaglandinom E1.
Rezultati. Tadalafil je značajno popravio erektilnu funk-
ciju (p <  0,001) za 7,40 poena IIEF skora, odnosno za
58% kod SEP2 i 60% kod SEP3 upitnika. Zabeleženo je
subjektivno bolje iskustvo sa tadalafilom u odnosu na
prethodnu terapiju za ED. U svakoj grupi došlo je do
značajnog poboljšanja IIEF skora (p < 0,001), značajnije
u grupi 2 (8,26±1,49 poena) u odnosu na srednje pobolj-
šanje u grupi 1 (6,27±1,35 poena). Vrednosti HbA1c na-
kon tri meseca su se smanjile za 2,26±1,62% (p < 0,001).
Zaključak. Tadalafil je efikasno sredstvo za lečenje ED
kod obolelih od DM. Davanje tadalafila bi moglo da za-
meni prostaglandinski test u nekim situacijama. Motivacija
u seksualnoj sferi dovodi do poboljšanja glikoregulacije
kod bolesnika sa DM.
Ključne reči:
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Introduction
One of the most perfidious diabetes mellitus (DM)
complications is autonomic neuropathy. The most dangerous
autonomic neuropathy complications are ‘mute infarction’
and a sudden death. However, the first symptoms to occur
are most commonly on the part of the urinary tract. In male
patients this is erectile dysfunction (ED), and in female pa-
tients reduced vagina lubrication and the absence of orgasm.
Due to common retrograde ejaculation (RE) complications of
ED male population is more exposed, which significantly af-
fects the quality of life and leads to sterility. That suggests to
the importance of an adequately taken anamnesis and the ap-
plication of sexology questionnaire in the prevention of se-
vere complications.
Diabetes patients are exposed to 4.1 times greater risk
of developing ED than non-diabetics of the same age,
whereas the risk in hyperlipoproteinemia patients is only 1.7
times greater, and in hypertonic patients the risk is 1.6 times
greater versus healthy population 
1. During the first 10 years
from the onset of the disease more than 50% of diabetes pa-
tients develop ED 
1. ED in DM male patients is more severe
and resistant to treatment than in male population with nor-
mal glycoregulation 
2. DM duration, therapy type and its
adequate application, age, dyslipidemia, hypertension and
risk factors, firstly nicotine, to a great extent define the ED
severity.
Both ED and DM strike more than 150 million people
worldwide, and according to the estimations by the year
2025 the number will doubled 
3−5.
The initial event for the normal erectile function is sex-
ual stimulation. As an answer to the sexual stimulation in
potent men nitrogen oxide (NO) is set off. NO actives gua-
nylin cyclase enzyme that further activates guanosine 3
phosphate (GTP) and creates cyclic 3’5’ guanosine mono-
phosphate (cGMP). cGMP leads to relaxed smooth artery
muscles, arterioles and sinusoidal corpus cavernous. Dis-
tended sinusoids comprise venulas on tunica albuginea and
in this way the blood stays trapped in the penis corpus cav-
ernous. Combination of the enhanced blood flow into the pe-
nis along with the labored discharge increases the intracaver-
nous pressure that quickly moves up to the systolic blood
pressure. With these pressure values the penis attains satis-
factory hardness for penetrating the vagina. The main phos-
phodiesterasis (PDE) that unbinds cGMP of the smooth penis
blood vessel muscles is PDE5. PDE5 inhibitors (tadalafil,
sildenafil citrate, vardenafil, etc.) block cGMP degradation
thus enhancing NO effect. Although these drugs are effective
in men with different etiology and ED degree, their effect
depends on the quality of pudendal bloodstream and endo-
thelial cells and pudendal nerves to free NO during the sex-
ual stimulation 
6−8. In patients with DM hyperglycemia it ag-
gravates NO discharge from these structures 
9−11. Accord-
ingly, the combination of vascular insufficiency, autonomic
neuropathy and endothelial dysfunction leads to more severe
ED in men with DM, and these patients have a weaker re-
sponse to PDE5 inhibitors than the patients of the same age
and without DM 
2.
Numerous researches 
12−15 show that PDE5 oral inhibi-
tors are effective and well tolerated in male patients with DM
and ED. Tadalafil is potent, reversible and selective PDE5
inhibitor. It is used as an oral pharmacotherapy in ED, psy-
chogenic, organic or mixed etiology 
16. The aim of this pilot
study was to determine the tadalafil efficacy and safety in
male patients with DM together with moderate to severe ED.
Methods
This pilot study was conducted in the Institute of  En-
docrinology, Diabetes and Metabolism Diseases, Clinical
Center of Serbia in cooperation with the Institute of  Urol-
ogy (urodyname researches), Institute of Physical Medicine
(electromyography researches) and Institute of Cardiovas-
cular Diseases. The study involved 30 male patients over
18 years of age, clinically diagnozed with type 1 or type 2
DM together with ED during the minimum period of 6
months.
The first examination included anamnesis, laboratory
tests with the glycaemia profile assessment and glycosylated
haemoglobin in blood (HbA1c), EKG, sexology question-
naire with 6 standardized questions − International Index of
Erectile Function (IIEF-6 score), physical examination and
the lower extremities polyneuropathy electromyography
tests. In all patients the ED severity was estimated through
IIEF score, Sexual Encounter Profile (SEP) questionnaire,
and in 20 patients also through the prostaglandin test (10−20
µg Prostaglandin E1 intracavernous) and the artificial erec-
tion 1−3 response was graduated. IIEF is a 15-question-
questionnaire divided into 5 sections related to erectile func-
tion (6 questions), orgasm (2 questions), sexual desire (2
questions), pleasure gained from sexual intercourse (3 ques-
tions), and general sexual satisfaction (2 questions).
The study used IIEF-6 score relating to the erection fre-
quency, the erection hardness, penetrating ability, preserving
frequency and the ability to maintain erection and the cer-
tainty of achieving erection, with the score of 1 to 30 points.
SEP questionnaire assumed 2 questions to which pa-
tients answered with YES/NO. SEP Q2: Were you able to
place your penis into the partner’s vagina? SEP question 3:
Did your erection last long enough for having a successful
sexual intercourse?
Patients were asked to compare tadalafil with the previ-
ous ED therapy (if applied) and to say if the erection
achieved with the help of tadalafil feels as natural or as arti-
ficially caused.
Patients agreed not to apply another ED therapy during
the study. They all gave their assent to the research and they
were all very motivated.
All the patients who had been using nitrates as well as
those who recently suffered a severe cardiovascular event,
stroke or the spinal cord injury were excluded from the
study. Patients with HbA1c values >  13% were also ex-
cluded. The study included male patients with microvascular
complications, including retinopathy.
For checking possible therapy joint effects and glu-
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month, and every third month IIEF-6 test, SEP 2,3 questions
and HbA1c were repeated.
According to the ED severity (IIEF score values at the
beginning of the study) patients were divided into 2 groups.
Differences in the IIEF score values and the number of
a YES responds of the SEP questionnaire at the beginning of
the research and at the end of the study were taken as a
leading parameter in evaluating the treatment efficacy.
The therapy side-effects were also monitored.
The drug study
The 20 mg tadalafil (Cialis) was used in this study. The
patients were given instructions to take the drug with water
once a week, on Fridays, and no more than 1 pill. They were
also explained that their sexual activity should not necessar-
ily be of a limited duration.
Statistic analysis
The results were presented as individual or medium
values with standard deviation. The obtained data were proc-
essed through the SPSS 13.0 software package. Chi-square
test, Independent sample t-test, 2 sample paired t-test with
the Bonferini’s correction were used.
Results
The study included 30 male patients of the average
46.27±11.09 age group (Table 1). Totally 14 (46.7%) pa-
tients were diagnozed with type 1 DM, whereas 16 (53.3%)
patients were diagnosed with type 2 DM.
Twenty (66.7%) patients experienced retrograde ejacu-
lation. Twelve patients experienced the complete absence of
ejaculation, whereas 8 patients had the reduced amount of
ejaculate. Except for 4 patients (13.3%), all others (25-
86.7%) were smokers of the long standing. The most com-
mon complications were polyneuropathy 30 (100%), reti-
nopathy (11 patients−36.6%), cardiac autonomic neuropathy
(4 patients−13.3%) and in 2 cases incipient nephropathy.
All the patients were on an antidiabetic therapy (Table 2).
Twenty-seven (90%) patients tried sildenafil (Viagra),
whereas 3 (10%) patients experienced intra-cavernous ther-
apy (prostaglandin E1, standard dosage) of limited duration.
Twenty five patients stated that compared with the previous
therapy they had had a more favorable experience with ta-
dalafil (Cialis), whereas 2 patients hadn’t noticed any differ-
ence. These favorable experiences were firstly explained by
the erection duration (and on the following day), and 5 out of
8 patients with reduced ejaculate said that there had been a
real improvement in the amount of ejaculate.
Tadalafil improved erectile function in all the patients.
The medium improvement in the IIEF score was 7.40 points
(41.67%). A significant improvement has also been recorded
in SEP 2, i.e. SEP 3 question, for 58% and 60% respectively.
It also come to a significant glucoregulation improvement
(Table 3).
Table 1
General characteristics of the patients with diabetes mellitus
and erectile dysfunction (ED)
Patients characteristics ґ ±SD
Age (years) 46.27±11.09
BMI (kg/m
2) 27.27±4.27
Diabetes duration (years) 13.33±6.96
ED duration (years) 2.46±0.89
BMI−Body Mass Index
Table 2
Number/percentage of diabetics treated with insulin
and/or oral antidiabetics
Antidiabetic therapy Patients
number %
Oral antidiabetics 9 30
Insulin 16 53.3
Insulin + oral antidiabetics 5 16.7
Table 3
Erectile function and glucoregulation improvement tendency in patients with erectile dysfunction and
diabetes mellitus treated with tadalafil (together with antidiabetic therapy)
Parameter Beginning 3rd month Difference Statistical significance
IIEF score (points) 10.53±3.49 18.07±4.42 7.53±1.71 p < 0.001
HbA1c (%) 9.51±1.95 7.25±0.89 2.26±1.62 p < 0.001
IIEF−International Index of erectile function; HbA1c−glycosylated haemoglobinStrana 402 VOJNOSANITETSKI PREGLED Volumen 64, Broj 6
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According to the values of the basic IIEF score the pa-
tients were subsequently divided into groups. Of all the pa-
tients, 36.7% diabetes patients had the severe ED (Table 4).
The group 1 included 11 patients who according to the
IIEF score had the most severe ED (Table 5). Six (54.5%) of
the patients were diagnozed with type 1 DM, and 5 (45.5%)
with type 2 DM. Only 1 (9%) patient didn’t have RE and all
the others had been previously using sildenafil citrate
(Viagra).
In the group 1 tadalafil improved the erectile function in
all the patients. Medium improvement of the IIEF score was
6.27±1.35 points compared with the basic values. HbA1c
values were also significantly reduced for 2.03±1.50% (Ta-
ble 6).
Erectile function and glucoregulation improvement ten-
dency in the patients with severe ED treated with tadalafil.
The goup 2 included 19 patients with moderate ED ac-
cording to the IIEF score (Table 7). Eight patients (42.1%)
were diagnozed with type 1 DM, and 11 (57.9%) with type 2
DM. Ten patients (52.6%) had already developed RE and
apart from 2 patients all others had been using sildenafil cit-
rate.
Ten patients had RE lasting for at least 6 months.
Table 4
Severity of erectile dysfunction (ED) according to the International Index of
Erectile Function (IIEF) score
Severity of
ED
IIEF score
Number of
examinees %
Severe 1-10 11 36.7
Moderate 11-16 19 63.3
Mild 17-25 0 0
Normal 26-30 0 0
Table 5
General characteristics of the patients with severe erectile dysfunction (ED)
and diabetes mellitus
Patients characteristics ґ±SD
Age (years) 41±10.05
BMI (kg/m
2) 27.8±5.61
Diabetes duration (years) 16.27±8.02
ED duration (years) 4.91±4.43
BMI−Body Mass Index
 Table 6
Erectile function and glucoregulation improvement tendency in the patients
with severe erectile dysfunction treated with tadalafil
Parameter Beginning 3rd month Difference Statistical significance
IIEF score (points) 6.45±2.07 12.73±1.85 6.27±1.35 p < 0.001
HbA1c (%) 9.26±1.51 7.23±0.94 2.03±1.50 p < 0.001
IIEF−International Index of Erectile Function; HbA1c−glycosylated haemoglobin in blood
Table 7
General characteristics of the patients with moderate erectile dysfunction (ED)
and diabetes mellitus
Patients characteristics ґ±SD
Age (years) 44.95±11.49
BMI (kg/m
2) 27.26±3.45
Diabetes duration (years) 11.63±5.82
ED duration (years) 1.82±0.87
BMI−Body Mass IndexVolumen 64, Broj 6 VOJNOSANITETSKI PREGLED Strana 403
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In all the patients tadalafil led to the IIEF score im-
provement of 8.26±1.49 points of the erectile function. A sig-
nificant HbA1c values reduction was also detected (Table 8).
There hasn’t been any statistically important age and
BMI difference between groups 1 and 2 and the HbA1c val-
ues. A statistically significant difference was detected in the
number of the IIEF score points that had improved after the
3-month-use of tadalafil in each group (p < 0.01) (Table 9).
According to expectations and considering the fact that their
ED was of less severe form, the increase was more signifi-
cant in the group 2.
Side-effects
Tadalafil was well tolerated. The most common side-
effects were headaches in 2 patients (6.7%), nausea in 2 pa-
tients (6.7%), backache (6.7%), and myalgia (3.3%). Due to
side-effects none of the patients discontinued the treatment.
There were no cases of myocardial infraction or myo-
cardial ischemia, as well as no significant changes in labo-
ratory values, EKG parameters or internist examinations.
Discussion
PDE5 inhibitors, which include tadalafil, by cGMP
blockade degradation enhance the NO effect and in this way
provide successful erection.
What separates tadalafil from the rest of PDE5 inhibi-
tors is the ability of acquiring the active drug concentration 2
hours after the intake, with the 17.5 h half-life and the effect
lasting up to 36 h. Drug absorption is not affected by food or
alcohol intake. As with other drugs from this group there is
the possibility of developing hypertension and when com-
bined with nitrates the risk of undesirable cardiovascular
events 
17.
Tadalafil improved the erectile function of both diabe-
tes groups even more significantly in the group with the less
severe ED. Medium improvement of 6.27±1.35 points of the
IIEF score was achieved in the group 1, and 8.26±1.49 in the
group 2 (p < 0.01).
After the 3-month-follow-up HbA1c values were sig-
nificantly lower. Judging from our experience with diabetes
patients we can say that the more attention they are given the
better discipline they show and the satisfactory glucoregula-
tion is achieved, which is obvious from the HbA1c values
that improved for 2.03% after 3 months bearing the statistical
significance (p < 0.01). Normoglycaemia in diabetes patients
affects the improvement of the endothelial function, en-
hanced NO bioavailability, and therefore a better reaction to
the PDE5 inhibitor treatment. If diabetes patients understand
that the erectile function and diabetes control are connected,
they are then more motivated to improve the disease control.
It is necessary to continue examining good diabetes control
effect on the erectile function and, due to the fact that the
male population is seriously exposed to the disease with the
better patient motivation purpose. In the Fonseca et al. 
15
study the patients were divided according to their HbA1c
values, into the patients with good glucoregulation (HbA1c
<7%), bad (HbA1c 7.0−9.5%) and distinctly bad (HbA1c
>9.5%) glucoregulation, which showed that the IIEF score
was lower in the group with the bad glucoregulation that
only points to the ED development glucoregulation signifi-
cance. In our study the drug efficacy was certainly affected
by a tendency to improve glucoregulation. Considering the
ED development etiology, organic factors (the existence of
neurogenic and vasculogenic components), but the psycho-
genic upgrade as well, compared to diabetes type as well as
the oral, combined or insulin therapy application no signifi-
cant difference in ED patients was detected.
Tadalafil improved erectile function in our patients and,
compared to the previously used preparations proved more
effective primarily regarding erection duration. A new mo-
ment is a subjective detection of the patients with scarce
Table 8
Erectile function and glucoregulation improvement tendency in the patients
with moderate erectile dysfunction
Parameter Beginning 3rd month Difference Statistical significance
IIEF score (points) 12.89±1.10 20.95±11.74 8.26±1.49 p < 0.001
HbA1c (%) 9.66<±2.20 7.26±0.90 2.40±1.71 p < 0.001
IIEF−International Index of Erectile Function; HbA1c−glycosylated haemoglobin in blood
Table 9
Better effects of tadalafil in the patients with moderate erectile dysfunction (ED)
and diabetes mellitus
Parameter
Group 1
(severe ED)
Group 2
(moderate ED)
Statistical
significance
Age (years) 41.55±10.05 44.95±11.49 NS
BMI (kg/m
2) 27.28±5.62 27.26±3.45 NS
IIEF score difference (points) 6.27±1.35 8.26±1.49 p < 0.01
HbA1c difference (%) 2.03±1.50 2.40±1.71 NS
IIEF−International Index of Erectile Function; HbA1c−glycosylated haemoglobin in blood; BMI−Body
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ejaculate, which is a tendency to increase ejaculate amount
that has not yet been recorded. In addition, the authors found
interesting a statement given by 27 patients who had previ-
ously been using sildenafil citrate, that while using tadalafil
most of them (20−74%) had a subjective sensation of a natu-
ral erection.
The patients who had experienced intracavernous ED
therapy experienced erection as artificial, whereas all 3 pa-
tients with that experience characterized tadalafil application
as having a more natural erection sensation.
Regarding side-effects, our study is not different from
the Fonseca et al. 
15 study. In no case the therapy was dis-
continued, and the stated changes (headaches, nausea) were
of a transitive nature, and  backache was attributed to the in-
creased physical activity and previously known polyneu-
ropathic discomforts.
Conclusion
Tadalafil proved to be an effective tool for treating ED
in diabetes patients. According to the expectations, the drug
efficacy was better in the patients with less severe ED. Com-
pared with the previously applied PDE5 inhibitors tadalafil
also proved to be more effective. Considering the prosta-
glandin test procedure complexity, we are of the opinion that
the application of this drug could in some cases replace the
prostaglandin test (difficulties in the intracavernous injection
application, the patients’ fear, side-effects, etc.). Tadafil side-
effects are very mild, almost negligible and no one has dis-
continued the therapy. Sexuality is an inalienable part of a
good quality life, and in this case the sexual sphere motiva-
tion proved to have a good effect on achieving satisfactory
glucoregulation in DM patients.
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